title: Surgery combined with peritonectomy procedures and intraperitoneal chemohyperthermia in abdominal cancers with peritoneal carcinomatosis: a phase II study.
abstract: OBJECTIVE
  To evaluate the tolerance of peritonectomy procedures (PP) combined with intraperitoneal chemohyperthermia (IPCH) in patients with peritoneal carcinomatosis (PC), a phase II study was carried out from January 1998 to September 2001.
  
  
  METHODS
  Fifty-six patients (35 females, mean age 49.3) were included for PC from colorectal cancer (26 patients), ovarian cancer (seven patients), gastric cancer (six patients), peritoneal mesothelioma (five patients), pseudomyxoma peritonei (seven patients), and miscellaneous reasons (five patients). Surgeries were performed mainly on advanced patients (40 patients stages 3 and 4 and 16 patients stages 2 and 1) and were synchronous in 36 patients. All patients underwent surgical resection of their primary tumor with PP and IPCH (with mitomycin C, cisplatinum, or both) with a closed sterile circuit and inflow temperatures ranging from 46 degrees to 48 degrees C. Three patients were included twice.
  
  
  RESULTS
  A macroscopic complete resection was performed in 27 cases. The mortality and morbidity rates were one of 56 and 16 of 56, respectively. The 2-year survival rate was 79.0% for patients with macroscopic complete resection and 44.7% for patients without macroscopic complete resection (P =.001). For the patients included twice, two are alive without evidence of disease, 54 and 47 months after the first procedure.
  
  
  CONCLUSIONS
  IPCH and PP are able to achieve unexpected long-term survival in patients with bulky PC. However, one must be careful when selecting the patients for such an aggressive treatment, as morbidity rate remains high even for an experienced team.
authors.affiliation: Surgical Department, Anesthesiology and Intensive Care Unit, Medical Oncology Department, Centre Hospitalo-Universitaire Lyon Sud, Pierre Bénite, France.
authors.forename: O
authors.initials: O
authors.lastname: Glehen
authors.forename: F
authors.initials: F
authors.lastname: Mithieux
authors.forename: D
authors.initials: D
authors.lastname: Osinsky
authors.forename: A C
authors.initials: AC
authors.lastname: Beaujard
authors.forename: G
authors.initials: G
authors.lastname: Freyer
authors.forename: Ph
authors.initials: P
authors.lastname: Guertsch
authors.forename: Y
authors.initials: Y
authors.lastname: Francois
authors.forename: P
authors.initials: P
authors.lastname: Peyrat
authors.forename: G
authors.initials: G
authors.lastname: Panteix
authors.forename: J
authors.initials: J
authors.lastname: Vignal
authors.forename: F N
authors.initials: FN
authors.lastname: Gilly
mesh_terms: D000230:Adenocarcinoma / Q000556:secondary / Q000628:therapy*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D005770:Gastrointestinal Neoplasms / Q000473:pathology / Q000628:therapy*; D006801:Humans; D006979:Hyperthermia, Induced; D007274:Injections, Intraperitoneal; D008297:Male; D008654:Mesothelioma / Q000556:secondary / Q000628:therapy*; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000473:pathology / Q000628:therapy*; D010534:Peritoneal Neoplasms / Q000556:secondary / Q000628:therapy*; D010537:Peritoneum / Q000601:surgery*; D011446:Prospective Studies; D015996:Survival Rate
chemical_list: D016685:Mitomycin; D002945:Cisplatin